EGFR and glioblastoma: In addition, clinical trials with the combination of MK-2206 and EGFR TKIs, such as erlotinib (OSI-774) and gefitinib, have been completed in NSCLC (NCT01294306 and NCT01147211), suggesting a potential combination strategy that might be utilized for the treatment of GBM.